NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences
01 mars 2024 14h00 HE
|
NMD Pharma
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences ClC-1 is a chloride ion channel specifically expressed...
Baylor Genetics Announces Neuromuscular Disorders Panel
22 mai 2023 10h05 HE
|
Baylor Genetics
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of a...
Cough Assist Devices Market Revenue to Cross USD 480 Mn by 2031 | TMR Study
06 avr. 2023 14h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, April 07, 2023 (GLOBE NEWSWIRE) -- The global cough assist devices market size was worth USD 218.5 Mn in 2021 and is expected to exceed value of USD 480.7 Mn by...
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
09 janv. 2023 07h00 HE
|
Lupin Ltd
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
14 déc. 2022 07h00 HE
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
14 déc. 2022 01h00 HE
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
08 juil. 2021 07h00 HE
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
08 juil. 2021 02h00 HE
|
NMD Pharma
PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14 juil. 2020 07h00 HE
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
14 juil. 2020 02h00 HE
|
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...